These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31741355)

  • 1. Improper Potency and Impurities in Compounded Polidocanol.
    Mann M; Munavalli GS; Amatangelo L; Morrison N
    J Drugs Dermatol; 2019 Nov; 18(11):1124-1127. PubMed ID: 31741355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel developments in foam sclerotherapy: Focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins.
    Star P; Connor DE; Parsi K
    Phlebology; 2018 Apr; 33(3):150-162. PubMed ID: 28166694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Safety and Efficacy of Foam Sclerotherapy With 1: 2 Polidocanol to Air Ratio Versus 1: 4 Ratio for the Treatment of Reticular Veins of the Lower Extremities.
    Hoss E; Kollipara R; Boen M; Alhaddad M; Goldman MP
    Dermatol Surg; 2020 Dec; 46(12):1715-1720. PubMed ID: 32947299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
    Uncu H
    Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of concentration congruity in six compounded polidocanol samples obtained for leg sclerotherapy.
    Weiss RA; Voigts R; Howell DJ
    Dermatol Surg; 2011 Jun; 37(6):812-5. PubMed ID: 21605244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Compound Sclerosant: Polidocanol-Bleomycin Foam.
    Hanshu Z; Shaohua L; Anwei C
    Dermatol Surg; 2020 Dec; 46(12):1712-1714. PubMed ID: 32769523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams.
    Carugo D; Ankrett DN; Zhao X; Zhang X; Hill M; O'Byrne V; Hoad J; Arif M; Wright DD; Lewis AL
    Phlebology; 2016 May; 31(4):283-95. PubMed ID: 26036246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleomycin Polidocanol Foam (BPF) Stability - In Vitro Evidence for the Effectiveness of a Novel Sclerosant for Venous Malformations.
    Sun Y; Gu H; Yang X; Cai R; Shang Y; Hu L; Wang Y; Chen H; Lin X
    Eur J Vasc Endovasc Surg; 2020 Jun; 59(6):1011-1018. PubMed ID: 32063463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA-approved sodium tetradecyl sulfate (STS) versus compounded STS for venous sclerotherapy.
    Almeida JI; Raines JK
    Dermatol Surg; 2007 Sep; 33(9):1037-44; discussion 1044. PubMed ID: 17760594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up.
    Moreno-Moraga J; Smarandache A; Pascu ML; Royo J; Trelles MA
    Phlebology; 2014 Dec; 29(10):658-66. PubMed ID: 23989971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Australian polidocanol (aethoxysklerol) study. Results at 2 years.
    Conrad P; Malouf GM; Stacey MC
    Dermatol Surg; 1995 Apr; 21(4):334-6; discussion 337-8. PubMed ID: 7728486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2).
    Todd KL; Wright DI;
    J Vasc Surg Venous Lymphat Disord; 2015 Jul; 3(3):258-264.e1. PubMed ID: 26992303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
    Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
    J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence.
    Todd KL; Wright DI;
    Phlebology; 2014 Oct; 29(9):608-18. PubMed ID: 23864535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe?
    Goldman MP
    Dermatol Surg; 2004 Dec; 30(12 Pt 1):1454-6; discussion 1456. PubMed ID: 15606731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indications for the sclerosing agent polidocanol (aetoxisclerol dexo, aethoxisklerol kreussler).
    Guex JJ
    J Dermatol Surg Oncol; 1993 Oct; 19(10):959-61. PubMed ID: 8408916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerotherapy for Reticular Veins in the Lower Limbs: A Triple-Blind Randomized Clinical Trial.
    Bertanha M; Jaldin RG; Moura R; Pimenta REF; Mariúba JVO; Lúcio Filho CEP; Alcantara GP; Padovani CR; Yoshida WB; Sobreira ML
    JAMA Dermatol; 2017 Dec; 153(12):1249-1255. PubMed ID: 28973414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results.
    Hamel-Desnos C; Desnos P; Wollmann JC; Ouvry P; Mako S; Allaert FA
    Dermatol Surg; 2003 Dec; 29(12):1170-5; discussion 1175. PubMed ID: 14725657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
    Rabe E; Otto J; Schliephake D; Pannier F
    Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.